和记黄埔-话题@MedSci

#和记黄埔#

6篇内容 | 637人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1632075, encodeId=91b516320e531, content=<a href='/topic/show?id=caeb39e68f0' target=_blank style='color:#2F92EE;'>#和记黄埔#</a>, objectTitle=和记黄埔启动HMPL-453治疗晚期肝内胆管癌的II期试验, objectType=article, longId=200232, objectId=130b2002327c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=130b2002327c, replyNumber=0, likeNumber=31, createdTime=2021-04-06, rootId=0, userName=canlab, userId=534321850921, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=130b2002327c, moduleTitle=和记黄埔启动HMPL-453治疗晚期肝内胆管癌的II期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=130b2002327c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1632073, encodeId=3cbe16320e324, content=<a href='/topic/show?id=caeb39e68f0' target=_blank style='color:#2F92EE;'>#和记黄埔#</a>, objectTitle=和记黄埔的Surufatinib获得FDA授予快速通道指定，用于治疗胰腺和非胰腺神经内分泌肿瘤, objectType=article, longId=192484, objectId=fb0c19248469, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fb0c19248469, replyNumber=0, likeNumber=33, createdTime=2020-09-01, rootId=0, userName=canlab, userId=534321850921, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fb0c19248469, moduleTitle=和记黄埔的Surufatinib获得FDA授予快速通道指定，用于治疗胰腺和非胰腺神经内分泌肿瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fb0c19248469)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1632074, encodeId=01df16320e439, content=<a href='/topic/show?id=caeb39e68f0' target=_blank style='color:#2F92EE;'>#和记黄埔#</a>, objectTitle=晚期神经内分泌肿瘤的治疗或迎新进展！和记黄埔已向EMA提交Surufatinib的营销授权申请, objectType=article, longId=199177, objectId=3bc11991e7f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3bc11991e7f6, replyNumber=0, likeNumber=27, createdTime=2021-01-25, rootId=0, userName=canlab, userId=534321850921, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3bc11991e7f6, moduleTitle=晚期神经内分泌肿瘤的治疗或迎新进展！和记黄埔已向EMA提交Surufatinib的营销授权申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3bc11991e7f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1632070, encodeId=d8e316320e0a5, content=<a href='/topic/show?id=caeb39e68f0' target=_blank style='color:#2F92EE;'>#和记黄埔#</a>, objectTitle=信达生物与和记黄埔医药宣布合作开展信迪利单抗与呋喹替尼用于实体瘤联合治疗的临床评估, objectType=article, longId=154784, objectId=d290154e847a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d290154e847a, replyNumber=0, likeNumber=29, createdTime=2019-02-25, rootId=0, userName=canlab, userId=534321850921, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d290154e847a, moduleTitle=信达生物与和记黄埔医药宣布合作开展信迪利单抗与呋喹替尼用于实体瘤联合治疗的临床评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d290154e847a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1632072, encodeId=f43416320e211, content=<a href='/topic/show?id=caeb39e68f0' target=_blank style='color:#2F92EE;'>#和记黄埔#</a>, objectTitle=和记黄埔医药在中国启动索凡替尼胆道癌IIb/III期临床试验, objectType=article, longId=163509, objectId=ad4a1635092f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad4a1635092f, replyNumber=0, likeNumber=34, createdTime=2019-10-09, rootId=0, userName=canlab, userId=534321850921, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad4a1635092f, moduleTitle=和记黄埔医药在中国启动索凡替尼胆道癌IIb/III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad4a1635092f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1632071, encodeId=aecb16320e1d9, content=<a href='/topic/show?id=caeb39e68f0' target=_blank style='color:#2F92EE;'>#和记黄埔#</a>, objectTitle=和记黄埔医药宣布修订2013年与礼来签订的呋喹替尼许可与合作协议, objectType=article, longId=156571, objectId=41c81565e191, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=41c81565e191, replyNumber=0, likeNumber=30, createdTime=2019-12-06, rootId=0, userName=canlab, userId=534321850921, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=41c81565e191, moduleTitle=和记黄埔医药宣布修订2013年与礼来签订的呋喹替尼许可与合作协议, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=41c81565e191)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

和记黄埔

2020-05-29

canlab (审核中...)

前往app查看评论内容

#和记黄埔#

和记黄埔启动HMPL-453治疗晚期肝内胆管癌的II期试验

2021-04-06

canlab (审核中...)

前往app查看评论内容

#和记黄埔#

和记黄埔的Surufatinib获得FDA授予快速通道指定，用于治疗胰腺和非胰腺神经内分泌肿瘤

2020-09-01

canlab (审核中...)

前往app查看评论内容

#和记黄埔#

晚期神经内分泌肿瘤的治疗或迎新进展！和记黄埔已向EMA提交Surufatinib的营销授权申请

2021-01-25

canlab (审核中...)

前往app查看评论内容

#和记黄埔#

信达生物与和记黄埔医药宣布合作开展信迪利单抗与呋喹替尼用于实体瘤联合治疗的临床评估

2019-02-25

canlab (审核中...)

前往app查看评论内容

#和记黄埔#

和记黄埔医药在中国启动索凡替尼胆道癌IIb/III期临床试验

2019-10-09

canlab (审核中...)

前往app查看评论内容

#和记黄埔#

和记黄埔医药宣布修订2013年与礼来签订的呋喹替尼许可与合作协议

2019-12-06

科室
- - 订阅+
  - 更多科室
工具
服务